, an analyst from Mizuho Securities, has initiated a new Buy rating on Apogee Therapeutics (APGE).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mizuho Securities has given its Buy rating due to a combination of factors that highlight the potential of Apogee Therapeutics’ APG777 in treating Th2 inflammatory diseases, particularly atopic dermatitis. The firm anticipates that Phase II results in 2026 will confirm the efficacy of APG777’s quarterly maintenance dosing, positioning it as a leading biologic treatment. Mizuho’s analysis suggests that APG777, when compared to lebrikizumab, offers sufficient drug exposure to maintain efficacy through week 52, which is crucial for its competitive edge.
Mizuho’s confidence is further bolstered by initial Phase II data showing that APG777’s mid-dose efficacy aligns well with existing IL-4/IL-13 biologics, but with a reduced injection burden. The firm also highlights the potential for higher doses of APG777 to achieve superior week 16 efficacy, potentially establishing it as a best-in-class treatment. The financial projections, including a risk-adjusted $3.4 billion in worldwide sales by 2035, support the positive outlook, with expectations of strong performance following the anticipated positive data in 2026.
In another report released on October 17, Citi also maintained a Buy rating on the stock with a $95.00 price target.